{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T18:18:55Z","timestamp":1776363535629,"version":"3.51.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["CRAD001CUS232T"],"award-info":[{"award-number":["CRAD001CUS232T"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Texas Neurofibromatosis Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40268-018-0248-6","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T11:47:20Z","timestamp":1538567240000},"page":"295-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial"],"prefix":"10.1007","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct02332902","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John M.","family":"Slopis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio","family":"Arevalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia S.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy F.","family":"Riascos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua A.","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patti","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-8515","authenticated-orcid":false,"given":"Mary Kay","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,3]]},"reference":[{"issue":"3","key":"248_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11910-012-0269-4","volume":"12","author":"DN Franz","year":"2012","unstructured":"Franz DN, Weiss BD. Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep. 2012;12(3):294\u2013301.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"248_CR2","unstructured":"Friedman JM. Neurofibromatosis 1. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews\u00ae. Seattle (WA): GeneReviews; 1993. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1109\/. Accessed 24 Apr 2018."},{"key":"248_CR3","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.","journal-title":"Nat Rev Dis Primers."},{"key":"248_CR4","doi-asserted-by":"publisher","first-page":"17005","DOI":"10.1038\/nrdp.2017.5","volume":"3","author":"L Adams","year":"2017","unstructured":"Adams L, Marshall L. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17005.","journal-title":"Nat Rev Dis Primers."},{"issue":"12","key":"248_CR5","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ajmg.a.32301","volume":"146A","author":"TM Roth","year":"2008","unstructured":"Roth TM, Petty EM, Barald KF. The role of steroid hormones in the NF1 phenotype: focus on pregnancy. Am J Med Genet A. 2008;146A(12):1624\u201333.","journal-title":"Am J Med Genet A."},{"issue":"7","key":"248_CR6","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","volume":"65","author":"B Dasgupta","year":"2005","unstructured":"Dasgupta B, Yi Y, Chen DY, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005;65(7):2755\u201360.","journal-title":"Cancer Res."},{"issue":"2","key":"248_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","volume":"19","author":"M Endo","year":"2013","unstructured":"Endo M, Yamamoto H, Setsu N, et al. Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19(2):450\u201361.","journal-title":"Clin Cancer Res."},{"issue":"24","key":"248_CR8","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1073\/pnas.0503224102","volume":"102","author":"CM Johannessen","year":"2005","unstructured":"Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA. 2005;102(24):8573\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"248_CR9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/1535-7163.MCT-07-2335","volume":"7","author":"G Johansson","year":"2008","unstructured":"Johansson G, Mahller YY, Collins MH, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008;7(5):1237\u201345.","journal-title":"Mol Cancer Ther."},{"issue":"3","key":"248_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.mrrev.2008.06.001","volume":"659","author":"M Rosner","year":"2008","unstructured":"Rosner M, Hanneder M, Siegel N, et al. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008;659(3):284\u201392.","journal-title":"Mutat Res."},{"issue":"8","key":"248_CR11","first-page":"895","volume":"22","author":"DK Sandsmark","year":"2007","unstructured":"Sandsmark DK, Pelletier C, Weber JD, et al. Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol. 2007;22(8):895\u2013903.","journal-title":"Histol Histopathol."},{"issue":"5","key":"248_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1158\/1535-7163.MCT-08-1008","volume":"8","author":"CY Zou","year":"2009","unstructured":"Zou CY, Smith KD, Zhu QS, et al. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009;8(5):1157\u201368.","journal-title":"Mol Cancer Ther."},{"issue":"5","key":"248_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335\u201348.","journal-title":"Nat Rev Cancer."},{"issue":"5","key":"248_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2003.09.002","volume":"29","author":"V Narayanan","year":"2003","unstructured":"Narayanan V. Tuberous sclerosis complex: genetics to pathogenesis. Pediatr Neurol. 2003;29(5):404\u20139.","journal-title":"Pediatr Neurol."},{"issue":"5","key":"248_CR15","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","volume":"16","author":"PJ Houghton","year":"2010","unstructured":"Houghton PJ. Everolimus. Clin Cancer Res. 2010;16(5):1368\u201372.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"248_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jaad.2007.05.021","volume":"57","author":"KV Paghdal","year":"2007","unstructured":"Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol. 2007;57(6):1046\u201350.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"248_CR17","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/0008-5472.CAN-07-5916","volume":"68","author":"B Hegedus","year":"2008","unstructured":"Hegedus B, Banerjee D, Yeh TH, et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 2008;68(5):1520\u20138.","journal-title":"Cancer Res."},{"issue":"1","key":"248_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cub.2007.11.066","volume":"18","author":"CM Johannessen","year":"2008","unstructured":"Johannessen CM, Johnson BW, Williams SM, et al. TORC1 is essential for NF1-associated malignancies. Curr Biol. 2008;18(1):56\u201362.","journal-title":"Curr Biol."},{"issue":"6","key":"248_CR19","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1542\/peds.2013-1224","volume":"133","author":"C Hua","year":"2014","unstructured":"Hua C, Zehou O, Ducassou S, et al. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas. Pediatrics. 2014;133(6):e1792\u20137.","journal-title":"Pediatrics."},{"issue":"4","key":"248_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/nou235","volume":"17","author":"B Weiss","year":"2015","unstructured":"Weiss B, Widemann BC, Wolters P, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015;17(4):596\u2013603.","journal-title":"Neuro Oncol."},{"issue":"6","key":"248_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/pbc.24873","volume":"61","author":"B Weiss","year":"2014","unstructured":"Weiss B, Widemann BC, Wolters P, et al. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014;61(6):982\u20136.","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"248_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140\u201351.","journal-title":"N Engl J Med."},{"issue":"6","key":"248_CR23","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz DN, Belousova E, Sparagana S, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One. 2016;11(6):e0158476.","journal-title":"PLoS One."}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-018-0248-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:47:54Z","timestamp":1628617674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-018-0248-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0248-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,3]]},"assertion":[{"value":"3 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by Novartis Pharmaceuticals (CRAD001CUS232T) and a research grant from the Texas Neurofibromatosis Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"John M. Slopis, Joshua A. Samuels, and Mary Kay Koenig report grants and personal fees from Novartis Pharmaceuticals. Keri C. Smith reports a grant from the Texas Neurofibromatosis Foundation. Joshua A. Samuels reports personal fees from MedStudy, Inc. Adelaide A. Hebert, Hope Northrup, and Mary Kay Koenig report provisional patents pending. John M. Slopis is employed by The University of Texas MD Anderson Cancer Center. Octavio Arevalo, Adelaide A. Hebert, Hope Northrup, Riascos, Joshua A. Samuels, Keri C. Smith, Mary Kay Koenig, Cynthia S. Bell, and Patti Tate are or were employed by The University of Texas Health Science Center at Houston at the time of this trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data generated or analyzed during this study are included in this published article and the Electronic Supplementary Material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The study protocol along with consent forms were reviewed and approved by the Committee for the Protection of Human Subjects at the University of Texas Health Science Center at Houston (HSC-MS-14-0758).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects consented to participate in this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}